Clinical trial · Interventional
CD4 in Combination With CHOP in Treating Non-cutaneous Peripheral TCell Lymphoma
A Multicentre Open-label Dose Escalation Tiral of Zanolimumab in Combination With CHOP Chemotherapy in Patients With CD4 Positive Non-cutaneous Peripheral T-cell Lymphoma With Nodal Involvement.
NCT00893516CI-TRIAL-00075847terminatedPhase 2Results postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Portfolio consolidation.
Summary
Brief summary (as posted)
Evaluation of CD4 in combination with CHO chemotherapy in subjects with nodal involvement of non cutaneous Tcell lymphoma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| T-cell Lymphoma | T-Cell Non-Hodgkin Lymphoma | ALIAS | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| CHOP | Drug | — | UNRESOLVED |
| CHOP + CD4 | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- 1
- description
- CHOP chemo therapy + CD4 therapy
- interventionNames
- Biological: CHOP + CD4
- type
- ACTIVE_COMPARATOR
- label
- 2
- description
- CHOP chemotherapy
- interventionNames
- Drug: CHOP
Primary outcomes (1)
- measure
- Primary Outcome Unavailable
- description
- All efforts to obtain data have been exhausted, therefore we have no data available to report.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * study is closed to enrollment Exclusion Criteria: * study is closed to enrollment
References
Publications (0)
Data not yet available
No reference posted for this study.